TMO
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc historical holders
total: 22
Egerton Capital Thermo Fisher Scientific Inc transactions over time
- Total transactions:
- 7
- New positions:
- 2
- Sold out:
- 2
- Added:
- 2
- Reduced:
- 1
- Held since:
- 2023 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2023 Q3
John Armitage has been an institutional investor in Thermo Fisher Scientific Inc (TMO) since 2019 Q2. According to 2026 Q2 report, John Armitage doesn't hold any shares. The fund/company first acquired TMO in 2019 Q2, initially purchasing 339,993 shares. John Armitage later completely sold out the position and reinvested in TMO again in 2023 Q1. Since the initial investment, Egerton Capital has made 6 more transactions in this position.
When did John Armitage exit their TMO position?
John Armitage no longer holds Thermo Fisher Scientific Inc (TMO). They sold off their entire position in 2023 Q3, closing out an investment that began in 2019 Q2.
When did John Armitage first invest in TMO?
John Armitage first invested in Thermo Fisher Scientific Inc (TMO) in 2019 Q2 at the reported quarter-end price of $293.68 per share, acquiring 339,993 shares in their initial purchase.
What is John Armitage's average cost basis for TMO?
Based on historical transaction data, John Armitage's estimated cost basis for Thermo Fisher Scientific Inc (TMO) is approximately $532.12 per share. This represents their average reported price* across all buy transactions.
Has John Armitage reinvested in TMO after selling?
Yes, John Armitage has shown renewed interest in Thermo Fisher Scientific Inc (TMO). After completely selling their position, they reinitiated an investment in 2023 Q1, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $532.12
- Weighted AVG sell price:
- $521.75
TMO transactions history by Egerton Capital
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q3
|
0.00%
|
0
|
$521.75
|
|
-100% (-562,479)
|
-3.03%
|
|
2023 Q2
|
3.03%
|
562,479
|
$521.75
|
$293,473,418
|
+426.91% (+455,728)
|
+2.45%
|
|
2023 Q1
|
0.66%
|
106,751
|
$576.37
|
$61,528,074
|
new
|
+0.66%
|
|
2020 Q1
|
0.00%
|
$324.87
|
-100% (-934,456)
|
|||
|
2019 Q4
|
2.17%
|
$324.87
|
+196.31% (+619,097)
|
|||
|
2019 Q3
|
0.66%
|
$291.27
|
-7.25% (-24,634)
|
|||
|
2019 Q2
|
0.73%
|
$293.68
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.